Dr. Serhat Gumruckcu At The ASGCT Covid-19 Symposium

Summary

• Fauci gives keynote speech at Symposium.
• Gamma-Delta T-cells key i combatting Covid-19.
• Not only a vaccine but possibly also a cure.

The American Society of Gene & Cell Therapy held an anticipated Covid-19 symposium, which opened with a keynote address from America’s most favored scientist Dr. Anthony Fauci (link 1)

Covid-19 is THE focuspoint of all major and minor pharma-companies as well as all National Health Services and Governments. The strain on health services as well as economy is overwhelning.  Enormous amounts of money and talent is zooming in on developing methods of testing, treating and preventing, so it is not surprising that the ASGCT this year held its symposium focussed on this subject only. It is also logical that such an event attracts specialists and scientist from around the globe..

Amongst the prestigious participants, apart from Dr. Fauci, were representatives of Astra Zeneca and Moderna - presenting their progress. Also present was Phd. Dr. Serhat Gumrukcu - for the second year in a row, his findings were presented as an abstract.

It is - in my book - no small accomplishment, to be presenting two consecutive years, at one of the most prestigious conferences regarding stem cell and gene technology, actually it is rather impressive (further info at . ASGCT.org )

The research presented in the abstract (see below) is done by Dr. Serhat Gumrucku from Seraph Institute; - and employees of Enochian Biosciences are mentioned as cowriters: This indicates, at least based on past history, that the development of any vaccine/cure is done combining Dr. Serhats research efforts capabilities.I assume that we will see the same development and end point as with the HBV-vaccine.  

Focus is of course first and foremost on finding a vaccine - but in my view it is almost equally important to develop a cure or a combination of the two that can rid those infected by covid-19 with the lasting effects of the disease- Link 2

Here is my transcript on the conclusion taken from the abstract - garnished with my own thoughts in brackets - italic.

Conclusion: There are dozens of different vaccines and treatments currently being developed for COVID-19. Inconsistent and short-lived antibody responses in some of the recovered individuals are concerning. (there are well documented reports that many of the Covid-19 survivors suffer from various sickness comparable to those that people who have endured meningitis)

gd T cells (Gamma-Delta-T-cells) are known to play an important role in cellular immunity against SARS infection (actually they are a key reason why - as seen here: link 3 )

We established that these cells also play a role against SARS-CoV-2 by demonstrating their enhanced expansion rates in the presence of viral protein S. Moreover, these ex vivo expanded gd T cells demonstrated memory cell properties, suggesting an important role of gd T cells in sustained immunity against SARS-CoV-2. (this is extremely important knowledge - since we have already seen mutations of the “original virus”)

end of quote

In other - layman’s words - to me it looks as if Serhat has demonstrated (in a test made on a small cohort of 17 patients) - that Gamma-Delta T-cells can play a/the key role in combatting Covid-19. I can only imagine the implications if the result can be replicated on a large scale cohort of 10-20,000 people 

Finding a LASTING vaccine - with the capability to adapt to the unavoidable mutations of Covid-19 is paramount - since there is little gained by eradicating a virus that no longer has the same RNA/DNA.

The results suggest that the gd T-cells have a memory that allows them to see through the mutations So - I might jumping to conclusions - and it might be a little farfetched, nonetheless - the results could implicate that Serhat & associates may have found a way of producing a future-proof vaccine and in addition possibly also a cure…

We will know more later :

Link 1 Fauci "Cautiously Optimistic" Regarding a COVID-19 Vaccine This YearLink 2 https://www.bmj.com/content/370/bmj.m3218

Link 3 Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals